The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Results from the Phase III ECHO trial of acalabrutinib plus BR in MCL
Michael Wang, MD, University of Texas MD Anderson Cancer Center, Houston, TX, presents the results of the Phase III ECHO study (NCT02972840), comparing acalabrutinib plus bendamustine and rituximab (BR) versus placebo plus BR in older patients with mantle cell lymphoma (MCL). The study found that the experimental arm showed a statistically significant improvement in progression-free survival (66 months vs. 49 months) compared to the control arm, though overall survival did not differ significantly. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
